AKT1 and lung carcinoma: Research on targeting the PI3K/Akt signaling pathway as a therapeutic target has been reported; for example, the PI3K/Akt signaling pathway selective inhibitor LY294002 can inhibit cell proliferation and induce cell apoptosis [31], reversing acquired chemotherapy resistance in esophageal cancer, lung cancer, and breast cancer cells [32,33].